Analyst Price Target is $9.50
▲ +1,148.69% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Curis in the last 3 months. The average price target is $9.50, with a high forecast of $15.00 and a low forecast of $4.00. The average price target represents a 1,148.69% upside from the last price of $0.76.
Current Consensus is
The current consensus among 4 investment analysts is to buy stock in Curis. This Buy consensus rating has held steady for over two years.
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.